Immune response to hepatitis B vaccine among HIV positive patients

Not Applicable

• Conditions: Condition 1: chronic hepatitis B. Condition 2: Human Immunodeficeincy Virus.; Chronic viral hepatitis B without delta-agent Chronic (viral) hepatitis B; HIV disease resulting in haematological and immunological abnormalities, not elsewhere classified

• Registration Number: IRCT2015072023251N1
• Lead Sponsor: Vice Chancellor of Hamadan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Isolated HBC Ab positive patients who infected with HIV
HBV DNA PCR positive, HBSAg positive, HBSAb positive Patients were excluded

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hbsab titer. Timepoint: pre and after vaccine, and repeated it in case of need. Method of measurement: quantitative serology.

Secondary Outcome Measures

Name	Time	Method
Probable Complication of Hepatitis B vaccine. Timepoint: will be done during the study. Method of measurement: Will be Measured by observing and questioning the patients.